EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Subscribe To Our Newsletter & Stay Updated